Sumavel DosePro(偏頭痛) - 預測與市場分析
Sumavel DosePro (Migraine) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 42 Pages
|Sumavel DosePro(偏頭痛) - 預測與市場分析 Sumavel DosePro (Migraine) - Forecast and Market Analysis to 2023|
|出版日期: 2014年03月31日||內容資訊: 英文 42 Pages||
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
Sumavel DosePro is currently the only commercially available prefilled disposable needle-free delivery system for subcutaneous injection. Its active ingredient is GSK's Imitrex (sumatriptan succinate) for acute treatment of migraines with or without aura. DosePro technology works by utilizing compressed nitrogen gas to penetrate the skin, under high pressure and into the subcutaneous tissue in one-tenth of a second (Sumavel DosePro prescribing information, 2011). The medicine is then absorbed into the bloodstream. The device was developed to enable self-administration of liquid drug formulations in single doses subcutaneously without a needle.